Home Newsfeeds Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target

Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target

Wolfe Research analyst Keith Stanley downgrades Magellan Midstream (NYSE:MMP) from Peer Perform to Underperform and announces $49 price target.

byBenzinga Newsdesk

November 16, 2022

1 minute read

Wolfe Research analyst Keith Stanley downgrades Magellan Midstream (NYSE:MMP) from Peer Perform to Underperform and announces $49 price target.

Lyell Immunopharma Presentations At SITC Highlight New Nonclinical Data On Product Candidates And Innovative Technology To Shorten TIL Manufacturing

By Benzinga Newsdesk

October 31, 9:09 AM

Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the

LYEL

Top 5 Health Care Stocks That Are Preparing To Pump In February

By Avi Kapoor

February 9, 9:35 AM

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

BIOL

Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024

By Benzinga Newsdesk

June 3, 12:02 PM

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1

CRNX